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Peptide directed phthalocyanine–gold
nanoparticles for selective photodynamic therapy
of EGFR overexpressing cancers†
Zoë Rachael Goddard, a Andrew Michael Beekman, a Marco M. D. Cominetti,a
Maria A. O'Connell, a Isabelle Chambrier,b Michael J. Cook,b María J. Marín, b
David A. Russell b and Mark Searcey *a
Gold nanoparticles, covalently functionalised with the photosensitiser C11Pc and PEG, were actively
targeted towards epidermal growth factor receptor overexpressing cancers using the peptide FITC-
βAAEYLRK. Selective phototoxicity was observed at nanomolar concentrations with minimal dark toxicity.
Photodynamic therapy (PDT) for cancer involves the
combination of a photosensitiser and light to convert
molecular triplet oxygen (3O2) to cytotoxic singlet oxygen (
1O2)
within cancerous cells, which ultimately leads to cell death.
Ideal photosensitisers for PDT are isomerically pure, have
good stability, a high molar extinction coefficient between
650–800 nm, a high quantum yield for singlet oxygen, have
no dark toxicity, interact preferentially with cancer cells and
clear relatively quickly from normal tissue.1,2 Most reported
photosensitisers are hydrophobic aromatics3 as they fulfil
many of these criteria, although the delivery of these
photosensitisers intravenously is particularly challenging. One
approach to overcoming the issues of photosensitiser
hydrophobicity is the use of a delivery vehicle such as gold
nanoparticles (AuNPs).2,4,5
AuNPs can be considered to be ideal drug carriers as they
are multivalent, chemically inert and minimally toxic.6 It has
previously been demonstrated that the functionalisation of
ca. 4 nm AuNPs with a mixed monolayer of the highly
hydrophobic zinc phthalocyanine C11Pc and poly(ethylene
glycol) (PEG) allows for the delivery of the active
photosensitiser in aqueous media.7 Antibodies and lectins
have been covalently attached to these nanosystems to
selectively deliver them to HER2 and Tf-antigen positive cell
lines respectively.7–9
While proteins are strong candidates for the targeted
delivery of AuNPs due to their extremely high selectivity
towards their target, the sensitivity of proteins towards pH,
temperature and organic solvents can lead to loss of activity
upon sample preparation. Alongside high production costs,
heterogeneity of samples can result in poor reproducibility.
Recently, the targeting ability of peptides has increased in
popularity10–15 as these chemically synthesised molecules can
overcome many of the disadvantages that proteins present,
while still maintaining selectivity towards the desired target.
The epidermal growth factor receptor (EGFR) is an
attractive target for cancer therapeutics as it is overexpressed
in a wide range of epithelial cancers, including lung,16
ovarian,17 colorectal18 and head and neck19 carcinomas.
EGFR has been previously selected as a target for peptide-
directed AuNPs for PDT. Here, the authors conjugated the
EGFR targeting peptide GE11 (YHWYGYTPQNVI) to
PEGylated AuNPs to selectively deliver the photosensitiser
Pc4 to glioblastoma.20,21 In these systems the Pc4 is adsorbed
to the ca. 5 nm gold core. These AuNPs were not internalised
upon binding, and were thought to show selective
phototoxicity through increased interaction with the EGFR,
via desorption of Pc4 from the AuNPs.20 However, in a
similar system targeting prostate specific membrane antigen,
significant off-target phototoxicity was observed, likely due to
the non-covalent attachment of the photosensitiser.22
While GE11 has been explored as a targeting ligand,
several other EGFR specific peptides have been reported in
the literature, including D4 (LARLLT)23 and AEYLR.24 These
shorter peptides are appealing due to their ease of synthesis,
while maintaining good selectivity for the EGFR. Of these,
AEYLR is of particular interest as it shows higher binding
affinity towards EGFR than D4,24 which in turn has better
uptake characteristics than GE11 as the hydrophobicity of
GE11 results in the aggregation of conjugates.25 AEYLR has
been used to selectively deliver liposomes26 and chitosan
microparticles27 towards EGFR expressing cancers. Here, we
describe for the first time the use of the superior EGFR
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targeting peptide AEYLR for the selective delivery of gold
nanoparticles to EGFR overexpressing cancer cells. In this
work, we functionalised ca. 4 nm AuNPs with a self-
assembled mixed monolayer of the photosensitiser C11Pc,
PEG and targeting peptide. The covalent attachment of the
photosensitiser removes the possibility of non-specific
phototoxicity due to desorption, resulting in a more selective
nanosystem.
The EGFR targeting peptide AEYLR was modified with a
lysine residue at the C-terminus to allow for site selective
amide bond formation to the PEG (HS-PEG-COOH), and with
a FITC-βAla at the N-terminus, allowing for visualisation of
this peptide, giving the directing peptide FITC-βAAEYLRK
(Fig. 1). This peptide was synthesised by solid phase
synthesis and purified by RP-HPLC.
Flow cytometry was used to confirm the expression level
of EGFR on A549 pulmonary adenocarcinoma (EGFR
overexpressing, ATCC no. CCL-185) and HEK293 embryonic
kidney (basal level EGFR, ATCC no. CRL-1573) cell lines.
Upon incubation with an EGFR antibody, A549 cells showed
a 31-fold increase in fluorescence, compared to a 6.7-fold
increase for HEK293 cells (Fig. S3, ESI†). To determine that
the modifications made to the peptide did not affect its
selectivity towards EGFR overexpressing cell lines, the
selective uptake of this modified peptide was confirmed by
fluorescence microscopy. Both cell lines were incubated for 1
h with the peptide, with only the A549 cells showing
significant fluorescence, and therefore peptide binding
(Fig. 2). Fluorescein was also incubated with both cell lines
under the same conditions to ensure that this increased
fluorescence observed in A549 cells was indeed due to
binding of the peptide sequence, and not due to an
interaction of the large FITC tag. The A549 cells did not show
any binding of fluorescein (Fig. S4, ESI†), suggesting the
uptake is due to the targeting of the peptide sequence itself.
The peptide was also assessed for mitogenic activity in both
A549 and HEK293 cells and no agonistic nor antagonistic
effects were observed (Fig. S5, ESI†).
Antibodies are commonly conjugated onto AuNPs post-
synthesis through EDC/NHS mediated amide bond
formation.28,29 These conjugations often give a poor yield due
to competing hydrolysis reactions. A key benefit of peptides
over antibodies is their significantly higher tolerability towards
organic solvents, meaning that FITC-βAAEYLRK could be
conjugated onto PEG prior to the synthesis of the AuNPs.
Tighter control over the concentration of targeting moiety on
the AuNP surface was possible by conjugation of peptide to
PEG pre-AuNP synthesis. The peptide was conjugated onto HS-
PEG-COOH via an amide linkage by stirring overnight with
HATU and DIPEA. The resulting mixture was evaporated to
dryness and used directly without purification for the synthesis
of AuNPs. Due to the polydispersity of the PEG, it was difficult
to purify at this stage but due to the efficiency of HATU for
amide bond formation and the excess of both peptide and
HATU, the reaction was assumed to go to completion. This was
further indicated as the peptide–PEG showed solubility in THF,
whereas the peptide itself was completely insoluble. Peptide–
C11Pc–PEG–AuNPs (Fig. 3a) were synthesised following the
one-pot protocol reported by Russell and co-workers to
synthesise ca. 4 nm AuNPs.7,30,31 The resulting AuNPs were
characterised by UV-vis and fluorescence spectroscopy (Fig. 3b
and S6, ESI†). The presence of both C11Pc and FITC could be
confirmed by their characteristic absorptions at ca. 645/696 nm
and 495 nm respectively (Fig. 3b). The solubility of the
nanoparticles in aqueous media confirmed that conjugation of
C11Pc onto AuNPs in a mixed monolayer with PEG was
successful as the photosensitiser itself is highly hydrophobic.
For this initial study, peptide–PEG and non-conjugated PEG
were added to the reaction mixture in a 50 : 50 ratio as
overcrowding of the AuNP surface with targeting ligand has
been shown to reduce targeting efficiency.32 Comparison of the
concentration of C11Pc and FITC on the surface of these
AuNPs, estimated from the UV-vis spectrum, suggested that
there were approximately 51 photosensitisers and 36 peptide
moieties per AuNP (see ESI†). These AuNPs were seen to be
below 5 nm in size due to the lack of a significant surface
plasmon absorbance band in the UV-vis spectrum.33 The
conjugation of FITC-βAAEYLRK to PEG prior to the synthesis of
the AuNPs allows for a much higher level of conjugation,
Fig. 1 The structure of the peptide FITC-βAAEYLRK, highlighting the
Lys (blue), βAla (pink) and FITC (green).
Fig. 2 a) Bright field and b) fluorescence microscopy images of 1)
A549 and 2) control HEK293 cells incubated with FITC-βAAEYLRK.
Scale bar = 100 μm.
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highlighted by previous reports that estimated only six
targeting antibodies were conjugated to C11Pc–PEG–AuNPs
using EDC/NHS post-synthesis.9
The ability of the synthesised nanoconjugates to produce
singlet oxygen was assessed using the singlet oxygen probe 9,10-
anthracenediyl-bis(methylene)dimalonic acid (ABMA). A control
of PEG–AuNPs was used to ensure that the recorded
photobleaching was due to the photosensitiser and not the PEG
functionalised gold core. While singlet oxygen lifetime is very
short in PBS, significant singlet oxygen production was observed
for the peptide–C11Pc–PEG–AuNPs (Fig. S7, ESI†). This was
slightly reduced compared to that of non-targeted C11Pc–PEG–
AuNPs, but this can be explained by the presence of tyrosine in
the peptide sequence, a known singlet oxygen quencher.34
Once the nanocarriers were confirmed to produce singlet
oxygen, they were tested for their ability to induce
phototoxicity in EGFR overexpressing cell lines. The peptide–
C11Pc–PEG–AuNPs were incubated with A549 cells for 3 h in
serum-free media, before the wells were washed with PBS to
remove any AuNPs that had not been internalised. The cells
were irradiated for six minutes at 633 nm with a 10 mW HeNe
laser (light dose 10.5 J cm−2), then incubated for 48 h before
a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay was used to assess
the cell viability. To account for dark toxicity, a second plate
of cells was treated with AuNPs in the same way, but not
irradiated. In each plate, staurosporine was used as a positive
control for cytotoxicity. The peptide–C11Pc–PEG–AuNPs
showed negligible dark toxicity in A549 cells at and below 200
nM C11Pc, while significant phototoxicity was observed; a 7%
cell viability was observed upon irradiation with 200 nM
peptide–C11Pc–PEG–AuNPs (Fig. 4a), the equivalent of 4 nM
AuNPs, and comparable to that of antibody-directed AuNPs.9
The IC50 of peptide–C11Pc–PEG–AuNPs in A549 cells was
found to be 105.8 nM C11Pc (91.68 nM, 121.5 nM 95% CI)
upon irradiation and >250 nM without irradiation (Fig. S8,
ESI†). A549 cells were also incubated with non-targeted
C11Pc–PEG–AuNPs at the same concentrations, and no
phototoxicity was observed (Fig. 4b), suggesting there is a
targeted photodynamic response for the peptide-conjugated
nanocarriers due to the presence of the EGFR targeting
peptide. To further confirm this, HEK293 cells were also
treated with peptide–C11Pc–PEG–AuNPs and C11Pc–PEG–
AuNPs, with no statistical difference observed between
irradiated and non-irradiated cells (Fig. S9, ESI†).
Interestingly, while there were no indications of cell death
upon visual examination, there was a decrease in proliferation
upon treatment of HEK293 cells with peptide–C11Pc–PEG–
Fig. 3 a) A schematic representation of the peptide–C11Pc–PEG–AuNPs with 50 : 50 PEG : peptide–PEG on the surface and b) the UV-vis extinction
spectrum of peptide–C11Pc–PEG–AuNPs in PBS, showing the presence of FITC at 495 nm and the characteristic double peak of C11Pc at 645 nm
and 696 nm.
Fig. 4 Cell viability of A549 cells treated with a) peptide–C11Pc–PEG–AuNPs, b) C11Pc–PEG–AuNPs or c) i) media, ii) peptide–C11Pc–PEG–AuNPs,
iii) FITC-βAAEYLRK, iv) FITC–PEG–AuNPs, v) peptide–PEG–AuNPs and vi) FITC–C11Pc–PEG–AuNPs either with (green) or without (blue) irradiation.
Where C11Pc was not present, cells were treated with 200 nM FITC. St = positive control of staurosporine. Error bars represent SE (n = 3).
Statistically significant differences are indicated by * at P ≤ 0.05, ** at P ≤ 0.01, *** at P ≤ 0.001, obtained using a two-tailed Student's t-test.
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AuNPs. The reason for this decrease in cell proliferation is
still under investigation, but the lack of phototoxicity suggests
there is a targeted photodynamic response towards EGFR
overexpressing cell lines.
While significant photodynamic activity was observed in
A549 cells after treatment with peptide–C11Pc–PEG–AuNPs, the
ability of fluorescein to act as a photosensitiser35 led to the
question of whether the photodynamic activity observed was
due to the C11Pc alone, or a combination of C11Pc and FITC.
The absorption of FITC is low at 633 nm36 and therefore it is
unlikely to be responsible for this activity, however, to confirm
this FITC–PEG–AuNPs and peptide–PEG–AuNPs were
synthesised to determine if the FITC tag was responsible for
any of the observed photodynamic activity. Control FITC–
C11Pc–PEG–AuNPs were also synthesised to confirm whether
the FITC tag was influencing the uptake of the nanocarriers, or
whether this was due to the targeting ability of the peptide. The
control AuNPs were characterised by UV-vis spectroscopy (Fig.
S10, ESI†). As the peptide itself possesses both the targeting
sequence and FITC, it was also tested for its ability to induce
phototoxicity. A549 cells were incubated with these
nanocarriers and the peptide for 3 h at 200 nM, a
concentration shown to elicit a significant photodynamic
response with peptide–C11Pc–PEG–AuNPs. The cells were
irradiated as previously described and no cell death was
observed for any of these control systems (Fig. 4c). These
controls highlight that the phototoxicity observed for the
peptide–C11Pc–PEG–AuNPs is due to the photocatalytic activity
of the C11Pc. The lack of phototoxicity from FITC–C11Pc–PEG–
AuNPs further confirms that the increased phototoxicity of
peptide-conjugated AuNPs is due to the presence of the
targeting peptide sequence itself, not the FITC tag.
In summary, we have demonstrated the viability of the
peptide FITC-βAAEYLRK as a targeting ligand for the delivery
of nanocarriers to EGFR overexpressing cell lines. We
designed the modified peptide FITC-βAAEYLRK to allow for
site selective conjugation onto PEG ligands. The FITC tag
allows for quantification of the peptide on the surface of the
AuNPs and provides an opportunity for intracellular imaging
of these nanosystems. The designed peptide–PEG was used
for the efficient synthesis of ca. 4 nm peptide–C11Pc–PEG–
AuNPs in a one-pot method, with approximately 51
photosensitisers and 36 targeting ligands per nanoparticle.
These nanocarriers are designed with the photosensitiser
covalently bound to the core, avoiding any off target
phototoxicity due to desorption of the photosensitiser. We
demonstrated that these peptide–C11Pc–PEG–AuNPs produce
singlet oxygen upon irradiation at 633 nm, and that selective
phototoxicity can be observed in EGFR overexpressing A549
cells. These nanosystems displayed nanomolar potency in
EGFR overexpressing A549 cells, with 200 nM C11Pc, the
equivalent of 4 nM AuNPs, exhibiting 7% viability following
irradiation and minimal dark toxicity. Finally, we
demonstrated that the phototoxicity of these peptide–C11Pc–
PEG–AuNPs is due to the dual effect of the targeting of the
peptide sequence and the photocatalytic activity of the
C11Pc, with the FITC tag neither causing phototoxicity nor
encouraging uptake of the AuNPs. These results, and the
relative tolerability of peptides towards organic solvents,
highlight peptides as a feasible alternative to antibodies for
the delivery of photosensitiser-baring nanoparticles to
cancers, with phototoxicity observed to be comparable to that
of antibody-directed C11Pc–PEG–AuNPs.9
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